IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.312 CHF | +7.04% |
|
+18.38% | +9.37% |
| May. 07 | Idorsia Secures Bondholders' Approval for Amendment to Terms of Outstanding Convertible Bonds | MT |
| May. 02 | Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 * | 138M 153M | Sales 2024 * | 243M 268M | Capitalization | 387M 426M |
|---|---|---|---|---|---|
| Net income 2023 * | -350M -386M | Net income 2024 * | -397M -438M | EV / Sales 2023 * | 10.6 x |
| Net Debt 2023 * | 1.08B 1.19B | Net Debt 2024 * | 1.12B 1.24B | EV / Sales 2024 * | 6.22 x |
| P/E ratio 2023 * |
-1.26
x | P/E ratio 2024 * |
-1.74
x | Employees | 650 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 58.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | +2.47% | ||
| 1 week | +7.36% | ||
| Current month | +19.34% | ||
| 1 month | -14.49% | ||
| 3 months | +44.68% | ||
| 6 months | +6.93% | ||
| Current year | +2.18% |
1 week
1.90
2.18
1 month
1.652.30
Current year
1.293.70
1 year
1.299.75
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
André Muller
DFI | Director of Finance/CFO | 60 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 2.312 | +7.04% | 447 324 |
| 24-05-10 | 2.16 | +2.47% | 345,944 |
| 24-05-08 | 2.108 | +0.38% | 330,767 |
| 24-05-07 | 2.1 | +7.53% | 1,048,879 |
| 24-05-06 | 1.953 | -2.93% | 497,043 |
Delayed Quote Swiss Exchange, May 10, 2024 at 11:31 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-05-21
- Q1 2024 Earnings Release - Q4 2023
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.16
CHF
Average target price
1.724
CHF
Spread / Average Target
-20.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.18% | 426M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| -0.03% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- IDIA Stock
